M-101
Reversal of effects from drink-spiking drugs (benzodiazepines, Z-drugs, GABA agonists)
Pre-clinicalActive
Key Facts
Indication
Reversal of effects from drink-spiking drugs (benzodiazepines, Z-drugs, GABA agonists)
Phase
Pre-clinical
Status
Active
Company
About Mithradote Bio
Mithradote Bio is a private, pre-revenue biotech focused on a critical unmet need in public health and personal safety: the prevention of drug-facilitated sexual assault. Its lead candidate, M-101, is a sublingual pan-antidote intended to counteract benzodiazepines, Z-drugs, and other GABA agonists used in drink-spiking. The company is in the pre-clinical or early development stage, building its team and technology to bring a portable, fast-acting countermeasure to market. This positions Mithradote at the intersection of biotechnology, harm reduction, and women's health.
View full company profile